Eagle Pharmaceuticals Receivables 2013-2023 | EGRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Eagle Pharmaceuticals receivables from 2013 to 2023. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Eagle Pharmaceuticals receivables from 2013 to 2023. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$196.7B
Stryker (SYK)	$142.8B
Boston Scientific (BSX)	$132.8B
EssilorLuxottica (ESLOY)	$110.9B
Medtronic (MDT)	$105.8B
Haleon (HLN)	$44.2B
Lonza Group Ag (LZAGY)	$43.1B
GE HealthCare Technologies (GEHC)	$37.1B
ResMed (RMD)	$35B
Terumo (TRUMY)	$29.6B
Koninklijke Philips (PHG)	$24.2B
Zimmer Biomet Holdings (ZBH)	$21.2B
Insulet (PODD)	$18.9B
Baxter (BAX)	$15.5B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$10B
Bio-Rad Laboratories (BIO)	$9.4B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.5B
Haemonetics (HAE)	$4.1B
Prestige Consumer Healthcare (PBH)	$4.1B
ICU Medical (ICUI)	$4B
Perrigo (PRGO)	$3.7B
Envista Holdings (NVST)	$3.4B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.8B
Neogen (NEOG)	$2.6B
LeMaitre Vascular (LMAT)	$2.3B
Green Thumb Industries (GTBIF)	$1.7B